{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T09:48:39Z","timestamp":1769852919036,"version":"3.49.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.clgc.2020.11.002","type":"journal-article","created":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T04:23:55Z","timestamp":1605241435000},"page":"e100-e119","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Second-Line Conservative Device-Assisted Intravesical Treatment in Selected Patients With Recurrent High-Risk Non\u2013Muscle-Invasive Bladder Cancer"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0564-7415","authenticated-orcid":false,"given":"Luca","family":"Di Gianfrancesco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Ragonese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3861-3545","authenticated-orcid":false,"given":"Giuseppe","family":"Palermo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4640-8354","authenticated-orcid":false,"given":"Emilio","family":"Sacco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"PierFrancesco","family":"Bassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Racioppi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2020.11.002_bib1","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","article-title":"European Association of Urology Guidelines on non\u2013muscle-invasive bladder cancer (TaT1 and carcinoma in situ)\u20142019 update","volume":"76","author":"Babjuk","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2020.11.002_bib2","first-page":"1296","article-title":"Early and late perioperative outcomes following radical cystectomy: 90-day readmissions, morbidity and mortality in a contemporary series","volume":"184","author":"Stimson","year":"2010","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2020.11.002_bib3","first-page":"777","article-title":"Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study","volume":"170","author":"Di Stasi","year":"2003","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2020.11.002_bib4","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00345-009-0384-2","article-title":"Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo\u00ae working party","volume":"27","author":"Witjes","year":"2009","journal-title":"World J Urol"},{"key":"10.1016\/j.clgc.2020.11.002_bib5","doi-asserted-by":"crossref","DOI":"10.3834\/uij.1944-5784.2011.12.15","article-title":"Definition of BCG failure in non\u2013muscle invasive bladder cancer in major urological guidelines","volume":"4","author":"Kamel","year":"2011","journal-title":"UroToday Int J"},{"key":"10.1016\/j.clgc.2020.11.002_bib6","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nrurol.2017.16","article-title":"BCG-unresponsive non\u2013muscle-invasive bladder cancer: recommendations from the IBCG","volume":"14","author":"Kamat","year":"2017","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.clgc.2020.11.002_bib7","series-title":"TNM Classification of Malignant Tumours","author":"Sobin","year":"2009"},{"key":"10.1016\/j.clgc.2020.11.002_bib8","series-title":"WHO Classification of Tumours of the Urinary System and Male Genital Organs","first-page":"29","article-title":"Tumours of the urinary system: non-invasive urothelial neoplasias","author":"Sauter","year":"2004"},{"key":"10.1016\/j.clgc.2020.11.002_bib9","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non\u2013muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group","volume":"34","author":"Kamat","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2020.11.002_bib10","series-title":"Sample Size Tables\u00a0for Clinical Studies","author":"Machin","year":"1997"},{"key":"10.1016\/j.clgc.2020.11.002_bib11","first-page":"180","article-title":"Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2020.11.002_bib12","first-page":"1283","article-title":"Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer","volume":"177","author":"Raj","year":"2007","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2020.11.002_bib13","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.eururo.2018.09.005","volume":"75","author":"Tan","year":"2019","journal-title":"Eur Urol"},{"issue":"suppl 5","key":"10.1016\/j.clgc.2020.11.002_bib14","first-page":"50","article-title":"Electro-motive drug administration (EMDA) of intravesical mitomycin-C in patients with high-risk non-invasive bladder cancer and failure of BCG immunotherapy","volume":"101","author":"Sockett","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.clgc.2020.11.002_bib15","first-page":"1313","article-title":"Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin","volume":"182","author":"Nativ","year":"2009","journal-title":"J\u00a0Urol"},{"issue":"6 pt 1","key":"10.1016\/j.clgc.2020.11.002_bib16","first-page":"1904","article-title":"Clinical experience with 5 aminolevulinic acid and photodynamic therapy for refractory superficial bladder cancer","volume":"165","author":"Waidelich","year":"2001","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2020.11.002_bib17","first-page":"708","article-title":"Combined chemohyperthermia: 10 year single center experience in 160 patients with nonmuscle invasive bladder cancer","volume":"192","author":"Arends","year":"2014","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2020.11.002_bib18","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000435788","article-title":"Predictive factors for time to progression after hyperthermic mitomycin C treatment for high-risk non\u2013muscle invasive urothelial carcinoma of the bladder: an observational cohort study of 97 patients","volume":"96","author":"Sooriakumaran","year":"2016","journal-title":"Urol Int"},{"key":"10.1016\/j.clgc.2020.11.002_bib19","first-page":"1200","article-title":"SWOG S0353: phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guerin","volume":"190","author":"Skinner","year":"2013","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2020.11.002_bib20","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(05)70472-1","article-title":"Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial","volume":"7","author":"Di Stasi","year":"2006","journal-title":"Lancet Oncol"},{"issue":"6 pt 1","key":"10.1016\/j.clgc.2020.11.002_bib21","first-page":"2414","article-title":"Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium","volume":"176","author":"Shariat","year":"2006","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2020.11.002_bib22","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.eururo.2014.01.029","article-title":"Propensity-matched comparison of morbidity and costs of open and robot-assisted radical cystectomies: a contemporary population-based analysis in the United States","volume":"66","author":"Leow","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2020.11.002_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.euo.2020.02.006","article-title":"Evidence-based assessment of current and emerging bladder-sparing therapies for non\u2013muscle-invasive bladder cancer after bacillus Calmette-Guerin therapy: a systematic review and meta-analysis","author":"Kamat","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.clgc.2020.11.002_bib24","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/1078-1439(95)00039-K","article-title":"Failure of intravesical interferon-alfa-2b for the treatment of patients with superficial bladder cancer previously failing intravesical BCG therapy","volume":"1","author":"Hudson","year":"1995","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2020.11.002_bib25","first-page":"1135","article-title":"Efficacy and safety of MCNA in patients with nonmuscle invasive bladder cancer at high risk for recurrence and progression after failed treatment with bacillus Calmette-Guerin","volume":"193","author":"Morales","year":"2015","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2020.11.002_bib26","first-page":"1124","article-title":"5-year follow-up of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer study group","volume":"161","author":"Malmstr\u00f6m","year":"1999","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2020.11.002_bib27","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1177\/1756287214541798","article-title":"Use of intravesical valrubicin in clinical practice for treatment of nonmuscle-invasive bladder cancer, including carcinoma in situ of the bladder","volume":"6","author":"Cookson","year":"2014","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.clgc.2020.11.002_bib28","first-page":"834","article-title":"Longterm survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Gu\u00e9rin therapy","volume":"189","author":"Barlow","year":"2013","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2020.11.002_bib29","first-page":"1633","article-title":"Phase II trial of intravesical nanoparticle albumin bound paclitaxel for the treatment of nonmuscle invasive urothelial carcinoma of the bladder after bacillus Calmette-Guerin treatment failure","volume":"192","author":"McKiernan","year":"2014","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2020.11.002_bib30","first-page":"817","article-title":"Factors affecting response to bacillus Calmette-Gu\u00e9rin plus interferon for urothelial carcinoma in situ","volume":"186","author":"Rosevear","year":"2011","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.clgc.2020.11.002_bib31","doi-asserted-by":"crossref","first-page":"35.e15","DOI":"10.1016\/j.urolonc.2013.01.009","article-title":"Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non\u2013muscle invasive bladder cancer","volume":"32","author":"Lightfoot","year":"2014","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2020.11.002_bib32","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11934-016-0594-2","article-title":"Experience with sequential intravesical gemcitabine and docetaxel as salvage therapy for non\u2013muscle invasive bladder cancer","volume":"17","author":"Velaer","year":"2016","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.clgc.2020.11.002_bib33","first-page":"761","article-title":"Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group","volume":"163","author":"Steinberg","year":"2000","journal-title":"J\u00a0Urol"},{"issue":"suppl 7","key":"10.1016\/j.clgc.2020.11.002_bib34","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1200\/JCO.2019.37.7_suppl.350","article-title":"KEYNOTE 057: phase II trial of pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-gu\u00e9rin (BCG)","volume":"37","author":"Balar","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2020.11.002_bib35","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1200\/JCO.2017.72.3064","article-title":"Intravesical rAd-IFN\u03b1\/Syn3 for patients with high-grade, bacillus Calmette-Guerin\u2013refractory or relapsed non\u2013muscle-invasive bladder cancer: a phase II randomized study","volume":"35","author":"Shore","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2020.11.002_bib36","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41585-018-0092-z","article-title":"Intravesical device\u2013assisted therapies for non\u2013muscle-invasive bladder cancer","volume":"15","author":"Tan","year":"2018","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.clgc.2020.11.002_bib37","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2147\/CEOR.S135065","article-title":"Cost of illness of urothelial bladder cancer in Italy","volume":"9","author":"Gerace","year":"2017","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.1016\/j.clgc.2020.11.002_bib39","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/S0022-5347(01)63174-4","article-title":"Intravesical electromotive drug administration technique: preliminary results and side effects","volume":"159","author":"Riedl","year":"1998","journal-title":"J Urol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767320302524?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767320302524?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:33:21Z","timestamp":1761564801000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767320302524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S1558767320302524"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2020.11.002","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Second-Line Conservative Device-Assisted Intravesical Treatment in Selected Patients With Recurrent High-Risk Non\u2013Muscle-Invasive Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2020.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}